ストックスクリーナーアプリを入手
0.964
3.60%
-0.036
アフターアワーズ：
.99
0.026
+2.70%
前日終値:
$1.00
開ける：
$1.02
24時間の取引高:
783.57K
Relative Volume:
0.68
時価総額：
$103.73M
収益：
-
当期純損益:
$-20.31M
株価収益率:
-3.6446
EPS:
-0.2645
ネットキャッシュフロー:
$-21.07M
1週間 パフォーマンス:
-9.06%
1か月 パフォーマンス:
-2.69%
6か月 パフォーマンス:
-4.55%
1年 パフォーマンス:
+30.48%
1日の値動き範囲:
$0.96
$1.02
1週間の範囲:
$0.93
$1.09
52週間の値動き範囲:
$0.3258
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Compare ONCY vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.964 | 107.61M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.90 | 119.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.67 | 82.71B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
844.41 | 52.43B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
336.19 | 45.01B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
362.14 | 39.23B | 4.98B | 69.60M | 525.67M | 0.5198 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-13 | 開始されました | Lake Street | Buy |
| 2022-10-06 | 開始されました | Maxim Group | Buy |
| 2021-02-17 | 開始されました | H.C. Wainwright | Buy |
Oncolytics Biotech Inc (ONCY) 最新ニュース
Aug Spikes: Can Oncolytics Biotech Inc expand its profit marginsMarket Trend Summary & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Patterns Watch: How is Oncolytics Biotech Inc managing supply chain issuesJuly 2025 PreEarnings & Community Consensus Trade Signals - baoquankhu1.vn
Smart Money: What is Oncolytics Biotech Incs 5 year growth outlookMarket Movers & Community Verified Trade Signals - baoquankhu1.vn
Registration Momentum Builds Across the Oncology Pipeline - The Globe and Mail
Public market insider buying at Oncolytics Biotech (ONC) - The Globe and Mail
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else - PR Newswire
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else - Benzinga
Assessing Oncolytics Biotech (ONCY) Valuation After FDA Fast Track Designation For Pelareorep - Yahoo Finance
Why Oncolytics Biotech (ONCY) Is Up 19.7% After FDA Fast Track For KRAS-Mutant Colorectal Cancer - Yahoo Finance
Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Oncolytics Biotech (ONCY) Is Up 19.7% After FDA Fast Track For KRAS-Mutant mCRC Regimen - Sahm
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Oncolytics Biotech (NASDAQ:ONCY) Insider Purchases $25,456.00 in Stock - MarketBeat
Insider Buying: Oncolytics Biotech (NASDAQ:ONCY) CEO Acquires 29,500 Shares of Stock - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Director Purchases $34,000.00 in Stock - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) CFO Kirk Look Acquires 12,000 Shares - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Director Wayne Pisano Buys 30,000 Shares - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Insider Thomas Charles Heineman Purchases 12,132 Shares - MarketBeat
Deborah Margaret Brown Buys 25,000 Shares of Oncolytics Biotech (NASDAQ:ONCY) Stock - MarketBeat
Will Oncolytics Biotech Inc. outperform tech stocksChart Signals & Weekly High Return Opportunities - mfd.ru
Why retail investors favor Oncolytics Biotech Inc. stockWeekly Trade Review & Detailed Earnings Play Strategies - mfd.ru
Oncolytics Biotech (NASDAQ:ONCY) Trading 1.3% HigherHere's Why - MarketBeat
Is Oncolytics Biotech Inc. forming a breakout patternMarket Trend Summary & Reliable Breakout Forecasts - mfd.ru
Precision Biologics Market Awakens to $71 Billion Opportunity - Intellectia AI
Analysts’ Top Healthcare Picks: Oncolytics Biotech (ONCY), NeuroPace (NPCE) - The Globe and Mail
New Highs: How sensitive is Oncolytics Biotech Inc to inflation2025 Bull vs Bear & Safe Capital Growth Stock Tips - baoquankhu1.vn
Oncolytics Biotech Forms Advisory Board to Advance Pelareorep in GI Cancers - MSN
Oncolytics Biotech Receives FDA Fast Track Designation - Intellectia AI
$207B Market Shift: The Race for Fast Track Approval in Oncology - Investing News Network
Oncolytics Biotech Inc - Baystreet.ca
Stocks in play: Oncolytics Biotech Inc - Barchart.com
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up - GlobeNewswire
Oncolytics receives FDA Fast Track Designation for pelareorep - Yahoo Finance
ONCY stock rallies on second fast track designation for experimental cancer drug - MSN
Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Yahoo Finance
Oncolytics Biotech receives FDA Fast Track for pelareorep - TipRanks
Oncolytics Biotech Inc Receives FDA Fast Track Designation for Pelareorep - TradingView
ONCY Stock Rallies On Second Fast Track Designation For Experimental Cancer Drug - Stocktwits
Oncolytics Biotech receives FDA fast track designation for pelareorep in 2L KRAS-mutant MSS metastatic colorectal cancer - marketscreener.com
Oncolytics Biotech (ONCY) Secures FDA Fast Track for Cancer Trea - GuruFocus
Oncolytics surges on Fast Track status for pelareorep in colorectal cancer - Seeking Alpha
Oncolytics Biotech stock soars after FDA grants Fast Track Designation By Investing.com - Investing.com South Africa
Oncolytics Biotech stock soars after FDA grants Fast Track Designation - Investing.com
Oncolytics (ONCY) Secures FDA Fast Track for Innovative Cancer T - GuruFocus
Oncolytics Biotech Showcases Promising Immunotherapy Advancements - timothysykes.com
FDA grants fast track designation to Oncolytics’ pelareorep for colorectal cancer - Investing.com
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer - The Manila Times
Oncolytics Biotech Receives Fast Track Designation for Pelareorep in Second-Line KRAS-Mutant MSS Metastatic Colorectal Cancer Following Promising Clinical Data - Quiver Quantitative
Oncolytics Biotech® Receives FDA Fast Track Designation for - GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
EPS Watch: Can Oncolytics Biotech Inc expand its profit marginsQuarterly Trade Summary & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Oncolytics Biotech Inc (ONCY) 財務データ
収益
当期純利益
現金流量
EPS
Oncolytics Biotech Inc (ONCY) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Kelly Jared | Chief Executive Officer |
Feb 11 '26 |
Buy |
0.84 |
5,600 |
4,682 |
79,500 |
| Look Kirk | Chief Financial Officer |
Feb 12 '26 |
Buy |
0.84 |
12,000 |
10,104 |
287,515 |
| Pisano Wayne | Director |
Feb 12 '26 |
Buy |
0.84 |
30,000 |
25,338 |
492,414 |
| Heineman Thomas Charles | Chief Medical Officer |
Feb 12 '26 |
Buy |
0.83 |
12,132 |
10,033 |
282,818 |
| Brown Deborah Margaret | Director |
Feb 12 '26 |
Buy |
0.85 |
25,000 |
21,240 |
109,851 |
| Hagerman Allison | VP, Product Development |
Feb 12 '26 |
Buy |
0.83 |
10,000 |
8,298 |
115,059 |
| Seizinger Bernd R. | Director |
Feb 11 '26 |
Buy |
0.83 |
60,000 |
49,590 |
526,991 |
| Seizinger Bernd R. | Director |
Feb 12 '26 |
Buy |
0.85 |
40,000 |
33,864 |
566,991 |
| Aromando Andrew | Chief Business Officer |
Feb 11 '26 |
Buy |
0.86 |
29,600 |
25,418 |
55,100 |
| Andrews Patricia S | Director |
Feb 12 '26 |
Buy |
0.86 |
35,400 |
30,292 |
78,128 |
0.34%
0.89%
大文字化:
|
ボリューム (24 時間):